PER percheron therapeutics limited

Ann: Percheron Holds International Advisory Boards, page-2

  1. 272 Posts.
    lightbulb Created with Sketch. 521
    “Avicursen has a novel mechanism in comparison to other DMD therapies,” commented Professor Thomas Voit, Director of the NIHR Great Ormond Street Hospital (GOSH) Biomedical Research Centre in London, UK, Chair of the European Advisory Board, and Principal Investigator for the ongoing international phase IIb clinical trial of avicursen in non-ambulant DMD. “Should the drug receive approval from regulatory agencies, we believe it may have a valuable role to play in the treatment of this very challenging disease.

    ”“We are grateful to the attendees for their time, and for their generous sharing of insights,” commented Percheron CEO, Dr James Garner. “The feedback we have received from these meetings will be of great value as we interpret emerging data from the avicursen clinical trial program, discuss the path forward with regulatory agencies, and consider how best to maximise the drug’s benefit for patients.”



    I think looking good!!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
0.000(0.00%)
Mkt cap ! $9.786M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $5.617K 624.0K

Buyers (Bids)

No. Vol. Price($)
25 6950862 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 899422 1
View Market Depth
Last trade - 16.10pm 28/07/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.